Aapro M (2018) CINV: still troubling patients after all these years. Support Care Cancer 26(Suppl 1):5–9. https://doi.org/10.1007/s00520-018-4131-3
Article PubMed PubMed Central Google Scholar
Yeo W, Mo FKF, Yip CCH et al (2021) Quality of life associated with nausea and vomiting from anthracycline-based chemotherapy: a pooled data analysis from three prospective trials. Oncologist 26(12):e2288–e2296. https://doi.org/10.1002/onco.13978
Article CAS PubMed PubMed Central Google Scholar
Kuchuk I, Bouganim N, Beusterien K et al (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142(1):101–107. https://doi.org/10.1007/s10549-013-2727-3
Article CAS PubMed Google Scholar
Schwartzberg L, Harrow B, Lal LS et al (2015) Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens. Am Health Drug Benefits 8(5):273–282
PubMed PubMed Central Google Scholar
Roeland EJ, Ruddy KJ, LeBlanc TW et al (2020) What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. J Natl Compr Canc Netw 18(6):676–681. https://doi.org/10.6004/jnccn.2019.7526
Article CAS PubMed Google Scholar
Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356–1367. https://doi.org/10.1056/NEJMra1515442
Article CAS PubMed Google Scholar
Hesketh PJ, Van Belle S, Aapro M et al (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39(8):1074–1080. https://doi.org/10.1016/S0959-8049(02)00674-3
Article CAS PubMed Google Scholar
Warr D (2014) Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol 722:192–196. https://doi.org/10.1016/j.ejphar.2013.10.015
Article CAS PubMed Google Scholar
Ettinger DS, Armstrong DK, Barbour S et al (2012) Antiemesis. JNCCN J Natl Compr Cancer Netw 10(4):456–485
Navari RM (2020) Nausea and vomiting in advanced cancer. Curr Treat Options Oncol 21(2):14. https://doi.org/10.1007/s11864-020-0704-8
Ghorbani M, Dehghani M, Fahimfar N et al (2022) FLOT (a chemotherapy regimen for gastric/esophagogastric junction cancer): to be treated as a highly emetogenic regimen or a moderately emetogenic one? Comparison of the emetogenic potential of FLOT versus FOLFOX and TAC regimens. Support Care Cancer 30(5):3865–3873. https://doi.org/10.1007/s00520-022-06832-x
Trammel M, Roederer M, Patel J et al (2013) Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Curr Oncol Rep 15(3):276–285. https://doi.org/10.1007/s11912-013-0312-x
Article CAS PubMed PubMed Central Google Scholar
Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(2):242–249. https://doi.org/10.1016/s1470-2045(19)30678-3
Article CAS PubMed Google Scholar
Nishimura J, Satoh T, Fukunaga M et al (2015) Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51(10):1274–1282. https://doi.org/10.1016/j.ejca.2015.03.024
Article CAS PubMed Google Scholar
Bubalo JS, Herrington JD, Takemoto M et al (2018) Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. Support Care Cancer 26(4):1273–1279. https://doi.org/10.1007/s00520-017-3950-y
Zhang L, Lu S, Feng J et al (2018) A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol 29(2):452–458. https://doi.org/10.1093/annonc/mdx698
Article CAS PubMed Google Scholar
Moradian S, Shahidsales S, Ghavam Nasiri MR et al (2014) Translation and psychometric assessment of the Persian version of the Rhodes Index of Nausea, Vomiting and Retching (INVR) scale for the assessment of chemotherapy-induced nausea and vomiting. Eur J Cancer Care (Engl Lang Ed) 23(6):811–818. https://doi.org/10.1111/ecc.12147
Ahmadi KR, Weale ME, Xue ZY et al (2005) A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 37(1):84–89. https://doi.org/10.1038/ng1488
Article CAS PubMed Google Scholar
Ding K, Kullo IJ (2007) Methods for the selection of tagging SNPs: a comparison of tagging efficiency and performance. Eur J Hum Genet 15(2):228–236. https://doi.org/10.1038/sj.ejhg.5201755
Article CAS PubMed Google Scholar
The International HapMap Project (2003) Nature 426(6968):789–796. https://doi.org/10.1038/nature02168
Xu Z, Taylor JA (2009) SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucl Acids Res 37(Web Server issue):W600-605. https://doi.org/10.1093/nar/gkp290
Article CAS PubMed PubMed Central Google Scholar
Conrad DF, Jakobsson M, Coop G et al (2006) A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. Nat Genet 38(11):1251–1260. https://doi.org/10.1038/ng1911
Article CAS PubMed Google Scholar
de Bakker PIW, Burtt NP, Graham RR et al (2006) Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet 38(11):1298–1303. https://doi.org/10.1038/ng1899
Article CAS PubMed Google Scholar
Hayase T, Sugino S, Moriya H et al (2015) TACR1 gene polymorphism and sex differences in postoperative nausea and vomiting. Anaesthesia 70(10):1148–1159. https://doi.org/10.1111/anae.13082
Article CAS PubMed Google Scholar
Fattahi Z, Beheshtian M, Mohseni M et al (2019) Iranome: a catalog of genomic variations in the Iranian population. Hum Mutat 40(11):1968–1984
Article CAS PubMed Google Scholar
Reed GH, Kent JO, Wittwer CT (2007) High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 8(6):597–608. https://doi.org/10.2217/14622416.8.6.597
Article CAS PubMed Google Scholar
Vossen RH, Aten E, Roos A et al (2009) High-resolution melting analysis (HRMA): more than just sequence variant screening. Hum Mutat 30(6):860–866. https://doi.org/10.1002/humu.21019
Article CAS PubMed Google Scholar
Słomka M, Sobalska-Kwapis M, Wachulec M et al (2017) High resolution melting (HRM) for high-throughput genotyping-limitations and caveats in practical case studies. Int J Mol Sci 18(11):2316. https://doi.org/10.3390/ijms18112316
Article CAS PubMed PubMed Central Google Scholar
Er TK, Chang JG (2012) High-resolution melting: applications in genetic disorders. Clin Chim Acta 414:197–201. https://doi.org/10.1016/j.cca.2012.09.012
Article CAS PubMed Google Scholar
Reed GH, Wittwer CT (2004) Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem 50(10):1748–1754. https://doi.org/10.1373/clinchem.2003.029751
Article CAS PubMed Google Scholar
Wojdacz TK, Dobrovic A, Hansen LL (2008) Methylation-sensitive high-resolution melting. Nat Protoc 3(12):1903–1908. https://doi.org/10.1038/nprot.2008.191
Article CAS PubMed Google Scholar
Erali M, Voelkerding KV, Wittwer CT (2008) High resolution melting applications for clinical laboratory medicine. Exp Mol Pathol 85(1):50–58. https://doi.org/10.1016/j.yexmp.2008.03.012
Article CAS PubMed PubMed Central Google Scholar
Auton A, Abecasis GR, Altshuler DM et al (2015) A global reference for human genetic variation. Nature 526(7571):68–74. https://doi.org/10.1038/nature15393
Article CAS PubMed Google Scholar
Untergasser A, Cutcutache I, Koressaar T et al (2012) Primer3—new capabilities and interfaces. Nucl Acids Res 40(15):e115–e115. https://doi.org/10.1093/nar/gks596
留言 (0)